Cigna Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cigna Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,031	Closed	-$210K	–	454
2022 Q4	$210K	Buy	+2,031	New	+$191K	0.04%	422
2020 Q3	–	Sell	-1,849	Closed	-$228K	–	656
2020 Q2	$228K	Buy	+1,849	New	+$184K	0.02%	632
2018 Q4	–	Sell	-2,256	Closed	-$208K	–	726
2018 Q3	$208K	Hold	2,256	–	–	0.02%	679
2018 Q2	$213K	Buy	+2,256	New	+$198K	0.02%	684
2017 Q4	–	Sell	-2,285	Closed	-$213K	–	895
2017 Q3	$213K	Sell	2,285 -92	-4%	-$8.13K	0.01%	814
2017 Q2	$216K	Buy	2,377 +36	+2%	+$3.27K	0.01%	758
2017 Q1	$205K	Buy	+2,341	New	+$208K	0.01%	702

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cigna Investments's BMRN Position: Q1 2023 in Review

Cigna Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 2,031 shares — an estimated $210K sold.

Cigna Investments first reported a position in BMRN in Q1 2017 and held it in 7 quarters. The position peaked at $228K in Q2 2020. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Cigna Investments reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Cigna Investments sold 2,031 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $210K.
Cigna Investments first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 7 quarters.
Cigna Investments's BioMarin Pharmaceuticals position peaked at $228K in Q2 2020.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Cigna Investments's 13F filing for Q1 2023, filed 11 May 2023.